Anticoagulation in Pregnancy

Cardiology Clinics

Volumn 30, Issue 3, 2012, Pages 395-405

  Goland, Sorel ^a   Elkayam, Uri ^b  

^a KAPLAN MEDICAL CENTER   (Israel)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anticoagulation; Antithrombotic therapy; Mechanical prosthetic valves; Pregnancy; Thromboembolism

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A ANTIBODY; DIGOXIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PROCAINAMIDE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY EMBOLISM; BLEEDING; CARDIOVERSION; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FETUS OUTCOME; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MATERNAL MORBIDITY; MATERNAL MORTALITY; MITRAL VALVE STENOSIS; OSTEOLYSIS; OSTEOPENIA; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERIPARTUM CARDIOMYOPATHY; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; THROMBOEMBOLISM; THROMBOSIS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION DISORDERS; CARDIOMYOPATHIES; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRENATAL CARE; THROMBOEMBOLISM;

EID: 84863879254     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2012.05.003     Document Type: Review

References (89)

1. Bremme K.A. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003, 16:153-168.
2. Franchini M. Haemostasis and pregnancy. Thromb Haemost 2006, 95:401-413.
3. Rosenkranz A., Hiden M., Leschnik B., et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost 2008, 99:331-337.
4. Clark P., Walker I. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001, 114:767-773.
5. Kjellberg U., Anderson N.E., Rosen S., et al. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 1999, 81:527-531.
6. James A.H. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Edu Program 2009, 277-285.
7. Heit J.A., Kobbervig C.E., James A.H., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005, 143:697-706.
8. James A.H., Bushnell C.D., Jamison M.G., et al. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005, 106:509-516.
9. James A.H., Jamison M.G., Biswas M.S., et al. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006, 113:1564-1571.
10. James A.H., Jamison M.G., Brancazio L.R., et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006, 194:1311-1315.
11. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004, 114:409-414.
12. McGehee W. Anticoagulation in pregnancy. Cardiac problems in pregnancy 1998, 407-417. Wiley-Liss, New York. 3rd edition. U. Elkayam, N. Gleicher (Eds.).
13. Bom D., Martinez E.E., Almeida P.A., et al. Pregnancy in patients with prosthetic heart valves: the effects of anticoagulation on mother, fetus and neonate. Am Heart J 1992, 124:413-417.
14. Sbarouni E., Oakley C.M. Outcome of pregnancy in women with valve prostheses. Br Heart J 1994, 71:196-201.
15. Chan W.S., Anand S., Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000, 160:191-196.
16. Elkayam U., Bitar F. Valvular heart disease and pregnancy: prosthetic valves part II. J Am Coll Cardiol 2005, 46:403-410.
17. Blickstein D., Blickstein I. The risk of fetal loss associated with warfarin anticoagulation. Int J Gynaecol Obstet 2002, 78:221-225.
18. Srivastava A.K., Gupta A.K., Singh A.V., et al. Effect of oral anticoagulant during pregnancy with prosthetic heart valve. Asian Cardiovasc Thorac Ann 2002, 10:306-309.
19. Meschengieser S.S., Fondevila C.G., Santarelli M.T., et al. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart 1999, 82:23-26.
20. Chen W.W., Chan C.S., Lee P.K., et al. Pregnancy in patients with prosthetic heart valves: an experience with 45 pregnancies. Q J Med 1982, 51:358-365.
21. Cotrufo M., De Feo M., De Santo L.S., et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002, 99:35-40.
22. Wesseling J., Van Driel D., Heymans H.S., et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost 2001, 85:609-613.
23. Bates S.M., Greer I.A., Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(Suppl 6):844S-886S.
24. Vitale N., De Eeo M., De Santo L.S., et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999, 33:1637-1641.
25. Sadler L., MeCowan L., White H., et al. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. Br J Obstet Gynecol 2000, 107:245-253.
26. Flessa H.C., Kapstrom A.B., Glueck H.I., et al. Placental transport of heparin. Am J Obstet Gynecol 1965, 93:570-573.
27. Schneider D., Heilmann L., Harenberg J. Placental transfer of low-molecular weight heparin. Geburtshilfe Frauenheilkd 1995, 55:93-98.
28. Barbour L.A., Pickard J. Controversies in thromboembolic disease during pregnancy: a critical review. Obstet Gynecol 1995, 86:621-633.
29. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1999, 168:1265-1270.
30. Maternal physiology in pregnancy. Normal and problem pregnancies 2002, 63-92. Churchill Livingstone, New York. 4th edition. M. Gordon, S. Gabbe, J. Niebyl (Eds.).
31. Brancazio L.R., Roperti K.A., Stierer R., et al. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995, 173:1240-1245.
32. Mazzolai L., Hohlfeld P., Spertini F., et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006, 108:1569-1570.
33. Evans W., Laifer S.A., McNanley T.J., et al. Management of thromboembolic disease associated with pregnancy. J Matern Fetal Med 1997, 6:21-27.
34. Casele H.L., Laifer S.A., Woelkers D.A., et al. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999, 181:1113-1117.
35. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999, 81:668-672.
36. Greer I.A., Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005, 106:401-407.
37. Casele H., Haney E.I., James A., et al. Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol 2006, 195:1109-1113.
38. James A.H. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol 2009, 29(3):326-331.
39. Bonow R.O., Carabello B.A., Chatterjee K., et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 52(13):e1-e142. American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
40. Bax J., Auricchio A., Baumgartner H., et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011, [Epub ahead of print].
41. Geelani M.A., Singh S., Verma A., et al. Anticoagulation in patients with mechanical valves during pregnancy. Asian Cardiovasc Thorac Ann 2005, 13(1):30-33.
42. Al-Lawati A.A., Venkitraman M., Al-Delaime T., et al. Pregnancy and mechanical heart valves replacement: dilemma of anticoagulation. Eur J Cardiothorac Surg 2002, 22(2):223-227.
43. Iturbe-Alessio I., Fonseca M.C., Mutchinik O., et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986, 315(22):1390-1393.
44. Khan A.O. Optic nerve dysfunction in a child following low-dose maternal warfarin exposure. Ophthalmic Genet 2007, 28(3):183-184.
45. Finkelstein Y., Chitayat D., Schechter T., et al. Motherisk rounds. Warfarin embryopathy following low-dose maternal exposure. J Obstet Gynaecol Can 2005, 27(7):702-706.
46. Sillesen M., Hjortdal V., Vejlstrup N., et al. Pregnancy with prosthetic heart valves: 30 years' nationwide experience in Denmark. Eur J Cardiothorac Surg 2011, 40(2):448-454.
47. Elkayam U., Singh H., Irani A., et al. Anticoagulation in pregnant women with prosthetic heart valve. J Cardiovasc Pharmacol Ther 2004, 9:107-115.
48. Lev-Ran O., Kramer A., Gurevitch J., et al. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg 2000, 69:264-265.
49. Berndt N., Khan I., Gallo R. A complication in anticoagulation using low-molecular weight heparin in a patient with mechanical valve prosthesis: a case report. J Heart Valve Dis 2000, 9:844-846.
50. Rowan J.A., McCowan L.M., Raudkivi P.J., et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol 2001, 185:633-637.
51. Arnaout M.S., Kazma H., Khalil A., et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic valves. Clin Exp Obstet Gynecol 1998, 25:101-104.
52. Oran B., Lee-Parritz A., Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 2004, 92:747-751.
53. Anticoagulation and enoxaparin use in patients with prosthetic heart valves and/or pregnancy. Clinical cardiology consensus reports 2002, vol. 3:1-20. American Health Consultants, Atlanta (GA).
54. Lovenox Injection [packet insert] 2004, Aventis Pharmaceuticals, Bridgewater (NJ).
55. Yinon Y., Siu S.C., Warshafsky C., et al. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol 2009, 104(9):1259-1263.
56. Abildgaard U., Sandset P.M., Hammerstrom J., et al. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res 2009, 124:262-267.
57. Quinn J., Von Klemperer K., Brooks R., et al. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience. Haematologica 2009, 94(11):1608-1612.
58. McLintock C., McCowan L.M., North R.A. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG 2009, 116(12):1585-1592.
59. Barbour L.A., Oja J.L., Schultz L.K. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004, 191:1024-1029.
60. Friedrich E., Hameed A.B. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol 2010, 30(4):253-257.
61. Fan J., Goland S., Khatri N., et al. Monitoring of anti Xa in pregnant patients with mechanical prosthetic valves receiving low molecular weight heparin: peak or trough levels?. Circulation 2011, 122:A18219. [abstract].
62. Reimold S.C., Rutherford J.D. Valvular heart disease in pregnancy: clinical practice. N Engl J Med 2003, 349:52-59.
63. Hameed A., Karaalp I.S., Tummala P.P., et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 2001, 37:893-899.
64. Hameed A., Akhter M.W., Bitar F., et al. Left atrial thrombosis in pregnant women with mitral stenosis and sinus rhythm. Am J Obstet Gynecol 2005, 193:501-504.
65. Sliwa K., Hilfiker-Kleiner D., Petrie M.C., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010, 12:767-778.
66. Amos A., Jaber W.A., Russell S.D. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006, 152:509-513.
67. Napporn A.G., Kane A., Damorou J.M., et al. Intraventricular thrombosis complicating peripartum idiopathic-myocardiopathy. Ann Cardiol Angeiol 2000, 49:309-314.
68. Goland S., Modi K., Bitar F., et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009, 15:645-665.
69. Agunanne E. Peripartum cardiomyopathy presenting with a pulmonary embolism: an unusual case. South Med J 2008, 101:646-647.
70. Box L.C., Hanak V., Arciniegas J.G. Dual coronary emboli in peripartum cardiomyopathy. Tex Heart Inst J 2004, 31:442-444.
71. Ibebuogu U.N., Thornton J.W., Reed G.L. An unusual case of peripartum cardiomyopathy manifesting with multiple thrombo-embolic phenomena. Thromb J 2007, 5:18.
72. Jha P., Jha S., Millane T.A. Peripartum cardiomyopathy complicated by pulmonary embolism and pulmonary hypertension. Eur J Obstet Gynecol Reprod Biol 2005, 123:121-123.
73. Quinn B., Doyle B., Mclnerney J. Postnatal pre-cordial pain, Pulmonary embolism or peripartum cardiomyopathy. Emerg Med J 2004, 21:746-747.
74. Shimamoto T., Marui A., Oda M., et al. A case of peripartum cardiomyopathy with recurrent left ventricular apical thrombus. Circ J 2008, 72:853-854.
75. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 2011, 58(7):659-670.
76. Briggs G.G., Freeman R.K., Yatte S.J. Drugs in pregnancy and lactation 2008, Wolters Kluwer, Philadelphia. 8th edition.
77. Chan F., Ngan Kee W.D. Idiopathic dilated cardiomyopathy presenting in pregnancy. Can J Anaesth 1999, 46(12):1146-1149.
78. Stergiopoulos K., Shiang E., Bench T. Pregnancy in patients with pre-existing cardiomyopathies. J Am Coll Cardiol 2011, 58(4):337-350.
79. Siu S.C., Sermer M., Colman J.M., et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001, 104:515-552.
80. Siu S.C., Sermer M., Harrison D.A., et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997, 96:2789-2794.
81. Grewal J., Siu S.C., Ross H., et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 2009, 55:45-52.
82. Shotan A., Ostrzega E., Mehra A., et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol 1997, 79:1061-1064.
83. Yarnoz M.J., Curtis A.B. More reasons why men and women are not the same (gender differences in electrophysiology and arrythmias). Am J Cardiol 2008, 101:1291-1296.
84. Gowda R.M., Punukollu G., Khan I.A., et al. Lone atrial fibrillation during pregnancy. Int J Cardiol 2003, 88:123-124.
85. Bryg R.J., Gordon P.R., Kudesia V.S., et al. Effect of pregnancy on pressure gradient in mitral stenosis. Am J Cardiol 1989, 63:384-386.
86. Whittemore R., Hobbins J.C., Engle M.A. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol 1982, 50:641-651.
87. Forfar J.C., Miller H.C., Toft A.D. Occult thyrotoxicosis: a correctable cause of " idiopathic" atrial fibrillation. Am J Cardiol 1979, 44:9-12.
88. DiCarlo-Meacham A., Dahlke J. Atrial fibrillation in pregnancy. Obstet Gynecol 2011, 117(2 Pt 2):489-492.
89. Fuster V., Rydén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guide for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and European Society of Cardiology committee for practice guidelines: developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:257-354.